

Technology Advisory Committee A Interests Register

Topic: Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

Publication Date: 5 February 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
James Fotheringham	Committee Member	Indirect - Financial	James has supported AstraZeneca in conducting systematic reviews in the area of treatment resistant hypertension, paid to my employer.	10/09/2024 12/11/2024	It was agreed that James' declaration would not prevent him from participating in discussions on this appraisal
Michael Chambers	Committee Member	Indirect – Financial	Michael has participated in an advisory panel for Pfizer (comparator company), but in an unrelated disease area (prostate cancer)	10/09/2024	It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal
Stella O'Brien	Committee Member	Indirect	Stella is a member of NHS England's Specialised Commissioning Genomics: Cancer Test Evaluation Working Group (TEWG). (Decision making but non-remunerated if that's relevant.) They consider applications for inclusion in the National Genomic Test Registry and make	10/09/2024	It was agreed that Stella's declaration would not prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			recommendations for tests that should enter routine commissioning.		
Dr Mukesh Bindlish Mukesh	Clinical Expert	Indirect – Financial	<p>Part of paid Advisory board by Menarini Stemline on UK landscape of Metastatic breast cancer (March 2023).</p> <p>Paid consultancy fee for ongoing clinical input with NICE submission for Elacestrant.</p> <p>Presenting at Menarini Stemline symposium at UK Oncology Forum June 24 on Elacestrant.</p> <p>Sponsorship by Menarini Stemline for ESMO 2024 congress.</p>	10/09/2024 12/11/2024	It was agreed that Dr Mukesh's declaration would not prevent him from providing expert advice to the committee.
Eleanor Pearce Willis		Indirect – Financial	<p>Employed by Breast Cancer Now who have declared the following:</p> <p>£10,500 from Menarini Stemline</p> <p>In August 2023, £109,985 sponsorship from Novartis towards our Service Pledge.</p>	10/09/2024 12/11/2024	It was agreed that Ms Pearce Willis' declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>In June 2023, £46,000 sponsorship from Novartis towards our Living with Secondary breast cancer face to face courses.</p> <p>In May 2023, £7,995 sponsorship from Seagen towards our Living with Secondary breast cancer face to face courses.</p> <p>In May 2023, £42,314.55 sponsorship from AstraZeneca towards our Ask our Nurses and Helpline services.</p> <p>In March 2023, £30,000 sponsorship from Pfizer towards our Living with Secondary breast cancer face to face courses.</p> <p>Breast Cancer Now hosts the UK Interdisciplinary Breast Cancer Symposium (UKIBCS) alongside a number of partners including professional bodies and charities. The meeting is held every 2 years</p>		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>and the UKIBCS provides a space to bring together those with an interest in breast cancer research and treatment to advance understanding of the disease. The event is managed by a third party who receive and process sponsorship on behalf of the host and partners. Sponsors have no control over the running of the event and editorial control has been retained by the UKIBCS executive board.</p> <p>In the past 12 months (since February 2023), this has included the following listed on this appraisal matrix:</p> <ul style="list-style-type: none"> £30,000 from Novartis towards the UKIBCS 2024 £50,000 from Novartis towards advertising space at UKIBCS 2024 £30,000 from AstraZeneca towards the UKIBCS 2024 		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> £3,000 from AstraZeneca for a small stand at the UKIBCS 2024 £15,500 from Menarini Stemline towards the UKIBCS 2024 £6,000 from Pfizer for an exhibition stand at the UKIBCS 2024 £3,000 from Eisai Ltd for an exhibition stand at the UKIBCS 2024 £3,000 from Pierre Fabre Ltd for an exhibition stand at the UKIBCS 2024 		